BioSpace News Archive

McCann Health has named Tim Jones as EVP, Executive Creative Director for McCann Health New York.

Trulieve Cannabis Corp. (CSE: TRUL & OTC: TCNNF) (“Trulieve” or the “Company”), a leading and top-performing cannabis company in the United States, today announced that Company founders have extended the lock-up restrictions in respect of 11,205,960 subordinate voting shares of the Company (on an as-converted basis),

Panaxia Labs Israel Ltd, the largest manufacturer of medical cannabis products in Israel announced positive topline results in its clinical trial evaluating bioavailability and safety of use of a variety of innovative delivery methods of medical cannabis products developed by the Panaxia Group.

Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Wednesday, January 15, 2020, at 11:00 a.m. Pacific time (2:00 p.m. Eastern time).

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced the appointment of Wendy L. Yarno as a Director of its Board of Directors..

Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases

Mesoblast Limited announced that the independent Data Monitoring Committee overseeing the Phase 3 trial of Revascor for advanced chronic heart failure has held its tenth and final scheduled meeting, and has recommended that the trial continue as planned.

DaVita Kidney Care today announced Dr. Jeffrey Giullian as chief medical officer (CMO).

IZI Medical Products, LLC (“IZI”), a leading interventional radiology medical device company and portfolio company of Shore Capital Partners, LLC (“Shore”), is pleased to announce it has acquired RadioMed, the manufacturer of VISICOIL™ implantable fiducial markers, from IBA S.A.

Eli Lilly and Company (NYSE: LLY) announced today the launch of TRIUMPH, a long-term, real-world evidence study of Emgality® (galcanezumab-gnlm).